MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with -mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Future oncology (London, England) Ročník 18; číslo 6; s. 639
Hlavní autori:	Cho, Byoung Chul, Felip, Enriqueta, Hayashi, Hidetoshi, Thomas, Michael, Lu, Shun, Besse, Benjamin, Sun, Tao, Martinez, Melissa, Sethi, Seema N, Shreeve, S Martin, Spira, Alexander I
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 01.02.2022
Predmet:	Acrylamides - adverse effects Acrylamides - therapeutic use Adolescent Adult Aniline Compounds - adverse effects Aniline Compounds - therapeutic use Antibodies, Bispecific - adverse effects Antibodies, Bispecific - therapeutic use Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Clinical Trials, Phase III as Topic ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Morpholines - adverse effects Morpholines - therapeutic use Multicenter Studies as Topic Mutation Neoplasm Metastasis Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Randomized Controlled Trials as Topic Research Design Young Adult amivantamab tyrosine kinase inhibitors EGFR mutations lazertinib non-small-cell lung cancer
ISSN:	1744-8301, 1744-8301
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!